Co-Transplantation of Pancreatic Islet Cells and Mesenchymal Bone Marrow Precursors on Titanium Nickelide Scaffolds in Alloxan-Induced Diabetes Mellitus

  • O. V. KokorevEmail author
  • V. N. Khodorenko
  • V. Yu. Serebrov
  • G. Ts. Dambaev
  • V. E. Gunter
Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)

We studied therapeutic activity of co-transplantation of allogeneic pancreatic islet cells and mesenchymal bone marrow progenitors on TiNi scaffolds in Wistar rats with experimental alloxan-induced diabetes mellitus. In preliminary experiments with co-culturing of cells in different proportions followed by their transplantation on tissue-engineered constructs, the optimum ratio of these cells was determined — 3:1. Regeneration was assessed by biochemical methods by the blood levels of glucose and glycosylated hemoglobin on days 15, 30, and 5. In the group with combined cell transplantation on TiNi scaffold, normalization of the studied biochemical parameters occurred earlier than after monotherapy with allogenic islet cells and was associated with an increase in animal lifespan. Normalization of the parameters of bone marrow hemopoiesis, in particular, the number of myelokaryocytes and erythroblasts was also noted.

Key Words

tissue engineering diabetes mellitus pancreatic islet cells mesenchymal stem cells porous TiNi 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borisov MA, Petrakova OS, Gvazava IG, Kalistratova EN, Vasiliev AV. Stem cells in the treatment of insulindependent diabetes mellitus. Acta Naturae. 2016;8(3):31-43.CrossRefGoogle Scholar
  2. 2.
    Vladimirskaya EB. Mesenchymal stem cells (MSCs) in cell therapy. Onkogematologiya. 2007;2(1):4-16. Russian.Google Scholar
  3. 3.
    Goldberg ED, Dygai AM, Zhdanov VV, Zyuz’kov GN, Fomina TI, Ermolaeva LA, Gur’yantseva LA, Khrichkova TY, Vetoshkina TV. State of stem cell pools in experimental diabetes mellitus. Bull. Exp. Biol. Med. 2006;142(1):108-111.CrossRefGoogle Scholar
  4. 4.
    Khubutiya MSh, Vagabov VA, Temnov AA, Sklifas AN. Paracrine mechanisms of antiinflammatory and organoprotective effectsin MBMPC transplantation. Transplantologiya. 2012;(1-2):20-32. Russian.Google Scholar
  5. 5.
    Khulup GYa, Mastistkaya SYu, Zafranskaya MM, Lamovskaya NV, Nizhegorodova DB, Ivanchik GI, Deneke B. Differentiation and immunomodulatory properties of mesenchymal stem cells as potential mechanisms of their positive effect in myocardial infarction. Vestn. Vitebsk. Gos. Med. Univer. 2009;8(1):12-21. Russian.Google Scholar
  6. 6.
    Shakhov VP, Khlusov IA, Dambaev GTs, Zaitsev KV, Salmina AB, Shakhova SS, Zagrebin LV, Volgushev SA. Introduction into Methods of Cell Culture and Bioengineering of Organs and Tissues. Tomsk, 2004. Russian.Google Scholar
  7. 7.
    Banerjee M, Kumar A, Bhonde RR. Reversal of experimental iabetes by multiple bone marrow transplantation. Biochem. Biophys. Res. Commun. 2005;328(1):318-325.CrossRefGoogle Scholar
  8. 8.
    Basta G, Montanucci P, Luca G, Boselli C, Noya G, Barbaro B, Qi M, Kinzer KP, Oberholzer J, Calafiore R. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts. Diabetes Care. 2011;34(11):2406-2409.CrossRefGoogle Scholar
  9. 9.
    El-Badri N, Ghoneim MA. Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges. J. Nucleic Acids. 2013;2013. ID 194858. doi:
  10. 10.
    Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front. Med. 2011;5(1):94-100.CrossRefGoogle Scholar
  11. 11.
    Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008; 36(6):733-741.CrossRefGoogle Scholar
  12. 12.
    Stull ND, Breite A, McCarthy R, Tersey SA, Mirmira RG. Mouse islet of langerhans isolation using a combination of purified collagenase and neutral protease. J. Vis. Exp. 2012;(67). pii: 4137. doi:
  13. 13.
    Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27(6):1421-1432.CrossRefGoogle Scholar
  14. 14.
    Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32(10):1887-1889.CrossRefGoogle Scholar
  15. 15.
    Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, Wang H, Hua B, Liu B, Sun L. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann. Rheum. Dis. 2011;70(7):1285-1288.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • O. V. Kokorev
    • 1
    • 2
    Email author
  • V. N. Khodorenko
    • 1
  • V. Yu. Serebrov
    • 2
  • G. Ts. Dambaev
    • 2
  • V. E. Gunter
    • 1
  1. 1.Research Institute of Medical Materials and Shape Memory ImplantsNational Research Tomsk State UniversityTomskRussia
  2. 2.Siberian State Medical University, Ministry of Health of the Russian FederationTomskRussia

Personalised recommendations